Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

INTRODUCTION: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675941/
https://www.ncbi.nlm.nih.gov/pubmed/31388559
http://dx.doi.org/10.1016/j.trci.2019.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675941/
https://www.ncbi.nlm.nih.gov/pubmed/31388559
http://dx.doi.org/10.1016/j.trci.2019.05.007

Ejemplares similares